Taken together, alterations of SIRT3 and mitochondrial p53 may be a marker for mitochondrial dysfunction in AD and therapeutic modulation of SIRT3 activity may be a useful strategy to ameliorate mitochondrial pathology in AD. This evidence concerns the gene SIRT3 and Alzheimer disease.